Evommune (EVMN) Profit After Tax (QoQ) (2024 - 2026)

Evommune (EVMN) Profit After Tax (QoQ) (2024 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,042.03 Bn	67,041.74 Bn	-
2	Nanobiotix	1,911.83 Bn	1,911.77 Bn	-
3	Akari Therapeutics	989.71 Bn	989.71 Bn	-
4	BeOne Medicines	471.62 Bn	466.83 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.97 Bn	114.72 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.98 Bn	61.22 Bn	3.31 Bn
7	Belite Bio	62.68 Bn	62.68 Bn	-
8	Argenx Se	55.75 Bn	50.57 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.49 Bn	34.48 Bn	959.66 Mn
10	Evommune	388.89 Mn	177.43 Mn	-

Download Data